Stock Watch: Novartis Softens Up The Market For BMS And Sanofi
Third-Quarter Earnings Suddenly Get Worse
Earnings season was not going too badly until a spate of self-inflicted wounds by BMS and Sanofi soured sentiment. Many new product launches remained too small to help.
You may also be interested in...
The French drugmaker is significantly upping its R&D spend and exiting consumer care, a strategy CEO Paul Hudson has stoutly defended following a slump in the share price.
J&J’s separation from its consumer division increased its cash, reduced its share count and provided interest income greater than third-quarter worldwide sales of some of its new drugs.
AstraZeneca is the latest GLP-1 agonist aspirant after Novo’s and Lilly’s recent earnings season successes. Already, a segmentation of potential patients and frantic competition among new GLP-1 agonists and drug combinations are emerging.